The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Flagged first, then by citations
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 301–400 of 1,001
High‐density lipoprotein in diabetes: Structural and functional relevance
Lui, D. T. W., & Tan, K. C. B. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14172 · Cited by 34
Zein, M. A., Khazzeka, A., Khoury, A. E., Zein, J. A., Dima, Z., & Eid, A. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.009 · Cited by 35
Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application
Toh, R. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17028 · Cited by 31
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
Scicali, R., Pino, A. D., Pavanello, C., Ossoli, A., Strazzella, A., Albertí, A., Mauro, S. D., Scamporrino, A., Urbano, F., Filippello, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56857-2 · Cited by 30
Tardif, J., Dubé, M., Pfeffer, M. A., Waters, D. D., Köenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., White, H. D., Heinonen, T. M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.007 · Cited by 30
LDL-C plays a causal role on T2DM: a Mendelian randomization analysis
Pan, W., Sun, W., Yang, S., Zhuang, H., Jiang, H., Ju, H., Wang, D., & Han, Y. (2020) · Aging · doi:10.18632/aging.102763 · Cited by 31
Sasaki, M., Delawary, M., Sakurai, H., Kobayashi, H., Nakao, N., Tsuru, H., Fukushima, Y., Honzumi, S., Moriyama, S., Wada, N., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314516 · Cited by 29
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?
Lappegård, K. T., Kjellmo, C. A., & Hovland, A. (2021) · Biomedicines · doi:10.3390/biomedicines9070836 · Cited by 30
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Pedro‐Botet, J., Ascaso, J. F., Barrios, V., de la Sierra, A., Escalada, J., Millán, J., Mostaza, J. M., Pérez‐Martínez, P., Pintó, X., Salas‐Salvadó, J., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s165740 · Cited by 31
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
Lee, Y., Lee, S. J., Kim, J. W., Lee, S., Kim, G.-S., Park, J. H., Cho, J., Kang, W. C., Yoon, H., Kim, W., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600283 · Cited by 37
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Identification of biomarkers in macrophages of atherosclerosis by microarray analysis
Huang, H., Jiang, X. M., Hao, M.-L., Shan, M., Qiu, Y., Hu, G.-F., Wang, Q., Yu, Z.-Q., Meng, L., & Zou, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1056-x · Cited by 29
Takaeko, Y., Matsui, S., Kajikawa, M., Maruhashi, T., Kishimoto, S., Hashimoto, H., Kihara, Y., Hida, E., Chayama, K., Goto, C., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.06.004 · Cited by 30
Marsche, G., Stadler, J. T., Kargl, J., & Holzer, M. (2022) · Antioxidants · doi:10.3390/antiox11030556 · Cited by 30
Is It Time for New Thinking About High-Density Lipoprotein?
Madsen, C. M., & Nordestgaard, B. G. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310727 · Cited by 29
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Kristensen, F., Christensen, D. H., Mortensen, M. B., Mæng, M., Kahlert, J. A., Sørensen, H. T., & Thomsen, R. W. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01921-5 · Cited by 29
HDL abnormalities in type 2 diabetes: Clinical implications
Martagón, A. J., Zubirán, R., González-Arellanes, R., Praget-Bracamontes, S., Rivera-Alcántara, J. A., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117213 · Cited by 30
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 30
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 28
Menon, V., Kumar, A., Patel, D. R., John, J. S., Riesmeyer, J., Weerakkody, G. J., Ruotolo, G., Wolski, K., McErlean, E. S., Cremer, P. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000943 · Cited by 31
Wanschel, A. C. B. A., Guizoni, D. M., Lorza‐Gil, E., Salerno, A. G., Paiva, A. A., Dorighello, G. G., Davel, A. P., Balkan, W., Hare, J. M., & Oliveira, H. C. F. (2021) · Biomolecules · doi:10.3390/biom11010069 · Cited by 28
Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice
Josefs, T., Basu, D., Vaisar, T., Arets, B., Kanter, J. E., Huggins, L.-A., Hu, Y., Liu, J., Clouet-Foraison, N., Heinecke, J. W., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317458 · Cited by 26
Heldner, M. R., Li, L., Lovett, N. G., Kubiak, M. M., Lyons, S., Rothwell, P. M., & Study, F. T. O. V. (2018) · Stroke · doi:10.1161/strokeaha.118.020913 · Cited by 28
Siewert, K. M., & Voight, B. F. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002239 · Cited by 28
Tada, H., Okada, H., Nomura, A., Takamura, M., & Kawashiri, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-019-1183-4 · Cited by 28
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
Mehta, N. N., Dangas, K., Ditmarsch, M., Rensen, P. C. N., Dicklin, M. R., & Kastelein, J. J. P. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106972 · Cited by 28
Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis
Yalçınkaya, M., & Tall, A. R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01323-w · Cited by 30
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 29
Lambadiari, V., Korakas, E., & Tsimihodimos, V. (2020) · Nutrients · doi:10.3390/nu12082204 · Cited by 29
George, R. T., Abuhatzira, L., Stoughton, S. M., Karathanasis, S. K., She, D., Jin, C., Buss, N. A. P. S., Bakker-Arkema, R. G., Ongstad, E. L., Koren, M. J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.119.014572 · Cited by 26
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Kim, H. J., Jeong, S., Oh, Y. H., Park, S. J., Cho, Y., & Park, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01805-8 · Cited by 30
MRBEE: A bias-corrected multivariable Mendelian randomization method
Lorincz‐Comi, N. J., Yang, Y., Li, G., & Zhu, X. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100290 · Cited by 31
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 28
Kim, J., Park, K. T., Jang, M. J., Park, T. K., Lee, J. M., Yang, J. H., Song, Y. B., Choi, S., Gwon, H., Lee, S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009517 · Cited by 26
Cardioprotective Properties of HDL: Structural and Functional Considerations
Pappa, E. T., Elisaf, M., Kostara, C. E., Bairaktari, E. T., & Tsimihodimos, V. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190201142321 · Cited by 28
HDL and Reverse Cholesterol Transport Biomarkers
Riggs, K. A., & Rohatgi, A. K. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-39 · Cited by 26
HDL in Morbidity and Mortality: A 40+ Year Perspective
Tall, A. R. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa148 · Cited by 26
Lay, J. E. L., Du, Q., Mehta, M. B., Bhagroo, N. V., Hummer, B. T., Falloon, J., Carlson, G. F., Rosenbaum, A. I., Jin, C., Kimko, H. H. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0602 · Cited by 27
Takahashi, D., Wada, H., Ogita, M., Yasuda, K., Nishio, R., Takeuchi, M., Shitara, J., Tsuboi, S., Dohi, T., Suwa, S., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.014 · Cited by 26
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Lipid-lowering treatment in peripheral artery disease
Katsiki, N., Giannoukas, A. D., Athyros, V. G., & Mikhailidis, D. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.003 · Cited by 26
CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both
Nicholls, S. J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1118 · Cited by 25
Anastasius, M. O., Luquain‐Costaz, C., Kockx, M., Jessup, W., & Kritharides, L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.08.002 · Cited by 28
Mortensen, M. B., Blaha, M. J., & Nordestgaard, B. G. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4759 · Cited by 27
Diaz, L., & Bielczyk-Maczyńska, E. (2025) · Open Biology · doi:10.1098/rsob.240372 · Cited by 27
Haghikia, A., & Landmesser, U. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.013 · Cited by 25
High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility
Vanags, L. Z., Wong, N. K. P., Nicholls, S. J., & Bursill, C. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310788 · Cited by 27
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
Abrahams, C., Woudberg, N. J., & Lecour, S. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01694-y · Cited by 25
Dorighello, G. G., Assis, L. H. P., Rentz, T., Morari, J., Santana, M. D. F. M., Passarelli, M., Ridgway, N. D., Vercesi, A. E., & Oliveira, H. C. F. (2022) · Antioxidants · doi:10.3390/antiox11091734 · Cited by 25
Tada, H., Usui, S., Sakata, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17040 · Cited by 26
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Lalic, K. S., Škrha, J., Valensi, P. E., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0667-2 · Cited by 25
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 26
Soran, H., Adam, S., & Durrington, P. N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.040 · Cited by 23
Li, Y., Chao, T.-H., Liu, P. Y., Ueng, K. C., & Yeh, H. I. (2018) · Europe PMC (PubMed Central) · doi:10.6515/acs.201809_34(5).20180629a · Cited by 24
Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke
Boulanger, M., Li, L., Lyons, S., Lovett, N. G., Kubiak, M. M., Silver, L. E., Touzé, E., Rothwell, P. M., Study, O. B. O. T. O. V., Study, O. B. O. T. O. V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007935 · Cited by 25
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 25
Bertrand, C., Saulnier, P., Potier, L., Croyal, M., Blanchard, V., Gand, E., Ragot, S., Schneider, F. M., Bocock, O., Baillet‐Blanco, L., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05326-x · Cited by 28
Kim, J. Y., Park, J. T., Kim, H. W., Chang, T. I., Kang, E. W., Ahn, C., Oh, K., Lee, J., Chung, W., Kim, Y., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.021731 · Cited by 24
Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis
Shah, S. M., Shah, J., Lakey, S., Garg, P., & Ripley, D. P. (2023) · Open Heart · doi:10.1136/openhrt-2022-002244 · Cited by 32
Update of HDL in atherosclerotic cardiovascular disease
Schoch, L., Alcover, S., Padró, T., Ben‐Aicha, S., Mendieta, G., Badimón, L., & Vilahur, G. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.10.002 · Cited by 25
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
Rehman, W. U., Yarkoni, M., Ilyas, M. A., Athar, F., Javaid, M., Ehsan, M. T., Khalid, M. T., Pasha, A. K., Selma, A. B., Yarkoni, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050152 · Cited by 26
Hartgers, M. L., Besseling, J., Stroes, E. S. G., Wittekoek, J., Rutten, J. H. W., Graaf, J. D., Visseren, F. L. J., Imholz, B. P. M., van Lennep, J. E. R., Huijgen, R., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.002 · Cited by 24
Shitara, J., Kasai, T., Konishi, H., Endo, H., Wada, H., Doi, S., Naito, R., Tsuboi, S., Ogita, M., Dohi, T., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-0970 · Cited by 25
Cholesteryl Ester Transfer Protein and Lipid Metabolism and Cardiovascular Diseases
Oliveira, H. C. F., & Raposo, H. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_2 · Cited by 24
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23
Shimizu, T., Miyazaki, O., Iwamoto, T., Usui, T., Sato, R., Hiraishi, C., & Yoshida, H. (2019) · Journal of Lipid Research · doi:10.1194/jlr.d086884 · Cited by 25
Diabetes and Vascular Disease: Is It All About Glycemia?
Vecchié, A., Montecucco, F., Carbone, F., Dallegri, F., & Bonaventura, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190830181944 · Cited by 23
LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis
Masson, W. M., Lobo, M., Siniawski, D. A., Masson, G., Cobo, A. L., & Molinero, G. B. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105655 · Cited by 23
Keng, M. J., Leal, J., Mafham, M. M., Bowman, L. J., Armitage, J., & Mihaylova, B. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.005 · Cited by 24
Aroner, S. A., Koch, M., Mukamal, K. J., Furtado, J. D., Stein, J. H., Tattersall, M. C., McClelland, R. L., & Jensen, M. K. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007824 · Cited by 23
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Rico, M. Á. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0563-4 · Cited by 23
Bonacina, F., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000642 · Cited by 23
Frikke‐Schmidt, R. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.005 · Cited by 23
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Metzinger, M. P., Saldanha, S., Gulati, J. S., Patel, K. V., El‐Ghazali, A., Deodhar, S., Joshi, P. H., Ayers, C. R., & Rohatgi, A. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018136 · Cited by 26
Bonaca, M. P., George, R. T., Morrow, D. A., Bergmark, B. A., Park, J., Abuhatzira, L., Vavere, A. L., Karathanasis, S. K., Jin, C., She, D., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab001 · Cited by 23
CETP Inhibitors — A New Inning?
Hegele, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711407 · Cited by 23
Statins increase Lp(a) plasma level: is this clinically relevant?
Pirillo, A., & Catapano, A. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz505 · Cited by 23
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?
Orekhov, A. N., & Sobenin, I. A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180320121137 · Cited by 22
The therapeutic potential of CETP inhibitors: a patent review
Wang, X., Li, W., Hao, L., Xie, H., Hao, C., Liu, C., Li, W., Xiong, X., & Zhao, D. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1439476 · Cited by 22
Capodanno, D., Mehran, R., Gibson, C. M., & Angiolillo, D. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1543399 · Cited by 22
Dixit, S. M., Ahsan, M., & Senapati, S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00301 · Cited by 22
High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study
Generoso, G., Benseñor, I. M., Santos, R. D., Staniak, H. L., Sharovsky, R., Santos, I. S., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., et al. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.10.006 · Cited by 21
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Banerjee, S., & De, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.016 · Cited by 22
High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?
Zvintzou, E., Karampela, D. S., Vakka, A., Xepapadaki, E., Karavia, E. A., Hatziri, A., Giannopoulou, P. C., & Kypreos, K. E. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106928 · Cited by 22
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 22
New insights into the therapeutic options to lower lipoprotein(a)
Baragetti, A., Dalt, L. D., & Norata, G. D. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14254 · Cited by 22
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Filippatos, T. D., Kei, A. A., & Elisaf, M. (2017) · Diseases · doi:10.3390/diseases5040021 · Cited by 22
Chroni, A., & Kardassis, D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180313114950 · Cited by 23
Samadi, S., Mehramiz, M., Kelesidis, T., Ghayour‐Mobarhan, M., Sahebkar, A. H., Esmaily, H., Moohebati, M., Farjami, Z., Ferns, G. A., Mohammadpour, A. H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28276 · Cited by 21
Apolipoprotein B: the Rosetta Stone of lipidology
Glavinovic, T., & Sniderman, A. D. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000596 · Cited by 22
Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition
Wu, B. J., Li, Y., Ong, K. L., Sun, Y., Shrestha, S., Hou, L., Johns, D. G., Barter, P. J., & Rye, K.-A. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310051 · Cited by 21
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
